drugset / Trial / NCT01052779

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779

Phase 2 Completed 162 enrolled AMAG Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in participants with chronic kidney disease (CKD).

Timeline

Start
2010-03-01
Primary completion
2011-07-19
Completion
2012-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 510 mg Intravenous
Comparator Iron sucrose Unknown 100 mg Intravenous
Comparator Iron sucrose Unknown 200 mg Intravenous